The class action lawsuit was brought on behalf of users of a diabetes drug ACTOS (pioglitazone hydrochloride) residing in Quebec against the manufacturers and distributors of ACTOS, Takeda Pharmaceutical Company, and its affiliates, and Eli Lilly.
ACTOS was approved for sale in Canada in August, 2000 to control blood sugar levels in people with Type 2 (non insulin-dependant) diabetes. A June 2011 study reported to the FDA found a clear link between pioglitazone and increased bladder cancer risk. As a result, the FDA in the U.S. issued a warning, now incorporated on the drug’s label, that use of ACTOS for more than one year may be associated with an increased risk of bladder cancer. French and German drug regulators suspended sales of ACTOS entirely following the results of similar studies in those countries.
CLASS: users of a diabetes drug ACTOS (pioglitazone hydrochloride) residing in Quebec